Get Informed: Campath
Campath Safety Report
Learn more about iGuard's risk ratings
- Please login or register (it's free) so iGuard can check how Campath interacts with other drugs and diseases in your profile.
How does it work in REAL PATIENTS?
iGuard is currently tracking fewer than 100 patients on this product.
iGuard needs more Campath users in our community before we can meaningfully start monitoring patient feedback for this product. If you use Campath, and are not yet registered with iGuard, please join us so we can start learning about this product sooner.
Global Patient Feedback for Campath (Alemtuzumab) ( Post a comment )
Question/Comment:
Campth is still in trials for Multiple Sclerosis. I am one of the lucky ones to get it! Next month (July 2009) i will get my second yearly dose. I absolutely expect the same horrible rash/hives that i got last July on the first day of infusion. I absolutely expect the horrible fatigues that lasted more than 3 weeks. BUT to not have to do the daily or weekly shots--and to have a greatly reduced rate of Exasberations is such a bonus! I have not had any MAJOR relapses--just small episodes of severe fatigue and loss of control of legs. I am very grateful to be in this study and will refer all patients to Campath when on the market!
41 year old Female – Source: iGuard United States
Posted: 2009-06-03 12:00:32
You may post comments for the benefit of other patients or post questions other patients might be able to answer. Comments are submitted for possible publication on the condition that they may be edited. Only your age and gender will be published with your comment, although your other user details will be securely recorded for verification purposes.
Comments may be either questions or answers to previously posted questions. Any iGuard.org user may post questions and reply.


1
Patient Comments about
Campath